Prospera Financial Services Inc acquired a new stake in shares of Immunovant, Inc. (NASDAQ:IMVT – Get Rating) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 9,135 shares of the company's stock, valued at approximately $50,000.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Dupont Capital Management Corp bought a new position in shares of Immunovant during the fourth quarter valued at approximately $232,000. Virginia Retirement Systems ET AL lifted its position in shares of Immunovant by 6.2% during the 4th quarter. Virginia Retirement Systems ET AL now owns 78,600 shares of the company's stock valued at $670,000 after acquiring an additional 4,600 shares during the last quarter. Arizona State Retirement System acquired a new stake in shares of Immunovant during the 4th quarter valued at $92,000. Swiss National Bank lifted its position in shares of Immunovant by 17.3% during the 4th quarter. Swiss National Bank now owns 88,700 shares of the company's stock valued at $756,000 after acquiring an additional 13,100 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of Immunovant by 136.6% in the fourth quarter. Bank of America Corp DE now owns 225,448 shares of the company's stock valued at $1,921,000 after purchasing an additional 130,142 shares in the last quarter. Institutional investors and hedge funds own 32.53% of the company's stock.
Get
Immunovant alerts:
Immunovant Stock Down 1.3 %
Shares of IMVT opened at $5.16 on Wednesday. The stock has a market cap of $601.22 million, a price-to-earnings ratio of -3.51 and a beta of 0.94. Immunovant, Inc. has a 12 month low of $3.14 and a 12 month high of $9.53. The company has a 50-day moving average price of $4.13 and a two-hundred day moving average price of $4.85.
Immunovant (NASDAQ:IMVT – Get Rating) last announced its quarterly earnings results on Wednesday, June 8th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.03). Equities research analysts expect that Immunovant, Inc. will post -1.66 EPS for the current fiscal year.
Analyst Ratings Changes
IMVT has been the topic of a number of research reports. Robert W. Baird dropped their price target on shares of Immunovant to $6.00 in a research note on Thursday, June 9th. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 price target on shares of Immunovant in a research report on Thursday, June 9th. Finally, UBS Group reduced their target price on shares of Immunovant to $7.00 in a research note on Friday, May 20th.
Immunovant Company Profile
(Get Rating)
Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia.
Recommended Stories
- Get a free copy of the StockNews.com research report on Immunovant (IMVT)
- Are 3M, Honeywell, GE Buys After Quarterly Reports?
- This Defense Stock Has Bullish Fundamentals AND Technicals
- CVS and Walgreens Show Why Investment Objectives Matter
- Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
- Are Medtronic And Intuitive Surgical Poised For Big Growth?
Want to see what other hedge funds are holding IMVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunovant, Inc. (NASDAQ:IMVT – Get Rating).
Receive News & Ratings for Immunovant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunovant and related companies with MarketBeat.com's FREE daily email newsletter.
